About Horus Pharma
Horus Pharma is a Healthcare company based in Saint-laurent-du-var (France) founded in 2003 by Martine Claret and Claude Claret. Ophthalmology pharmaceutical products are developed by Horus Pharma. Horus Pharma has raised $25.17 million across 3 funding rounds from investors including Eurazeo, European Union and EIC Fund. Horus Pharma has completed 1 acquisition, including Inocare. Its chief executive, as recorded, is Claude Claret. Horus Pharma offers products and services including Medicinal Products and Medical Devices. Its focus areas include Traditional Pharmaceuticals, Traditional Nutraceuticals and Diversified.
Company details
Horus Pharma was established in 2003 as a developer of pharmaceutical products focused on ophthalmology. Core activities involve the creation and distribution of specialized treatments for eye conditions. The company is co-led by Martine Claret in the role of President and Claude Claret as CEO. Operations center on pharmaceutical innovation within the healthcare sector, with a presence accessible via horus-pharma.com.
- Headquarters Saint-laurent-du-var, France
- Founders Martine Claret, Claude Claret
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website horus-pharma.com/gb
- Social LinkedIn Facebook YouTube
- Legal Name Horus Pharma
Products & Services of Horus Pharma
Horus Pharma offers a comprehensive portfolio of products and services, including Medicinal Products and Medical Devices.
Medicinal products are developed for conditions such as eye health and infections.
Medical devices are provided for surgical and diagnostic purposes in ophthalmology.
Apps and channels of Horus Pharma
its YouTube channel Horus Pharma has 1.55K subscribers and 30 videos.
Videos from Horus Pharma
The most watched videos on Horus Pharma's YouTube channel, Horus Pharma (1.55K subscribers). Click a video to play it here.
More on Horus Pharma.
Funding Insights of Horus Pharma
Horus Pharma has successfully raised a total of $25.17M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $25.17 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25.17M
- Total Rounds 3
- Last Round Series B — $25.17M
- First Round $63,000
(Oct 2014)
- Investors Count 3
All 3 funding rounds of Horus Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $25.17M | Series B | – | – | |
| Mar 2015 | $54,250 | Grant | – | – | |
| Oct 2014 | $63,000 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Horus Pharma
Horus Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Eurazeo, European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and debt investments are managed across multiple sectors. | 1969 | eurazeo.com | Paris, France | |
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Horus Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Horus Pharma
2 people are tracked at Horus Pharma (2 in leadership).
| Name | Role | Group |
|---|---|---|
Martine Claret | Co-Founder & President | Leadership |
Claude Claret | Co-Founder & CEO | Leadership |
Complete people profiles for Horus Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Horus Pharma
Horus Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Inocare.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of ophthalmic products for eye surface health and retinal support | inocare.ro | Romania | 0 | Nov 2024 | •••• |
Complete acquisition details for Horus Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Horus Pharma
4 dated milestones of Horus Pharma across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Horus Pharma is founded.
- Funding First funding round of $63K.
- Funding Latest funding round, Series B, of $25.2M.
- Acquisition Acquires Inocare.
Web traffic of Horus Pharma
The website of Horus Pharma (horus-pharma.com) receives about 5.9K visits a month and ranks #2,628,409 among all websites worldwide, #3,589 in Biotechnology and Pharmaceuticals.
- Monthly visits5.9K
▼ 17.2% vs previous month
- Unique visitors3K
per month
- Global rank#2,628,409
among all websites
- Category rank#3,589
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit2.4
- Average visit1 min 09 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with Horus Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
roche.fr | roche.fr | 100% | #533,892 | – | |
alcon.fr | alcon.fr | 91% | – | ||
| ipsen.com | 80% | 112.9K | #336,868 | View details | |
distrib3.com | distrib3.com | 80% | – | ||
msd-france.com | msd-france.com | 80% | #3,623,093 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Horus Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Horus Pharma
Horus Pharma was founded in 2003 and raised its 1st funding round 11 years after it was founded.
Horus Pharma is headquartered in Saint-laurent-du-var, France. It is registered at Saint-laurent-du-var, Alpes-maritimes, France.
Claude Claret is the CEO of Horus Pharma, as recorded in our data. They have also founded this company.
Horus Pharma is a funded company, having raised a total of $25.17M across 3 funding rounds to date. The company's 1st funding round was a Grant of $63K, raised on Oct 2014.
Horus Pharma was established in 2003 as a developer of pharmaceutical products focused on ophthalmology. Core activities involve the creation and distribution of specialized treatments for eye conditions. The company is co-led by Martine Claret in the role of President and Claude Claret as CEO. Operations center on pharmaceutical innovation within the healthcare sector, with a presence accessible via horus-pharma.com.
Horus Pharma offers Medicinal Products and Medical Devices.
Horus Pharma has made 1 acquisition, including Inocare.
Horus Pharma has 3 investors. Key investors include Eurazeo, European Union, and EIC Fund.
Horus Pharma operates through Horus Pharma.